Pharmaceuticals is an integrated drug discovery company engaged in the validation of
therapeutic targets and the identification of novel lead compounds for pharmaceutical
development. ACADIA has developed a platform of proprietary breakthrough technologies for
rapid analysis of gene function. ACADIA’s technology, including the patented
Receptor Selection and Amplification Technology (R-SAT™), allows the Company to
exploit the paradigm shift occurring in the pharmaceutical industry, whereby novel drug
targets are increasingly identified through genomic initiatives.
Pharmaceuticals, Inc. was organized in 1984 to bring a fresh approach to the discovery
of new therapeutic drugs for treatment of cancer, AIDS and other serious diseases. Agouron has developed
and mobilized an engineering approach to the design of novel synthetic drugs based upon
the molecular structures of target proteins which play key roles in human disease. Known
as protein structure-based drug design, this approach uses innovations from a variety of
scientific disciplines and substantially overcomes the technical barriers to traditional
drug discovery. From this technology, Agouron has built a new kind of foundation for one
of the pharmaceutical industry’s most elusive assets: a real product pipeline.
is a worldwide supplier of industrial gases and equipment, specialty and intermediate
chemicals, and environmental and energy systems.
The world’s largest independent biotechnology company, Amgen, was founded in Thousand Oaks, California in 1980 as
AMGen (Applied Molecular Genetics). Amgen’s corporate mission is to be the world leader in
developing and delivering important, cost-effective therapeutics based on advanced
cellular and molecular biology.
Amphora Discovery Corp aims to exploit chemical genomics–to create a
comprehensive database of information articulating the action of a large
chemical library on thousands of therapeutic targets. The Amphora database
will provide a map of the molecular features of potential new drugs and how
they affect their targets. This database takes the human genome effort another
step forward toward benefiting mankind by providing this map of potential new
drugs. The expectation is that this map will shorten, by at least a year, the
time from biology discovery to useful medicine.
a leader in the design and development of a new class of pharmaceuticals that target
intracellular signaling pathways to alter the course of disease. The Company is
concentrating the majority of its resources on four drug discovery programs. The first
three programs involve developing small molecules that inhibit signaling pathways
in cells responsible for allergy/asthma, immune-related disorders and osteoporosis. The
fourth program employs small molecules to gain control of signaling pathways,
providing a means to regulate the production of therapeutic proteins by engineered cells
within the body.
ArQule, Inc. is a
leading chemistry company in accelerated drug discovery using its high throughput lead
generation and lead optimization technologies. ArQule provides new pathways to product
discovery by integrating five core technologies – – modular building blocks technology,
structure – guided design, high speed parallel chemical synthesis, information technology
and an Automated Molecular Assembly Plant (AMAPTM) parallel synthesis system to accelerate
the identification and optimization of drug and product development candidates in the
pharmaceutical, biotechnology, and agrochemical industries. ArQule is based in Medford,
Services of Delaware Inc. presents New and Innovative Chromatography
Applications & Analytical Services for Industries.
Searching out new and diverse libraries of Organic and Natural Compounds
Setting New Standards in Control and Preparation of Organic Compounds
Special Attention and dedication to High Throughput Screening Programs
Astra is an
international pharmaceutical company in a phase of rapid growth. The company focuses on
areas of disease in which its proficiency in research can satisfy important medical needs.
ATOFINA Chemicals, Inc. is a customer-focused, innovative supplier with a
company-wide commitment to excellence. Our company is segmented into the
following business groups: Intermediate and Fine Chemicals, Performance
Polymers, Performance Chemicals.
Pharmaceuticals, Inc. is a leader in the integration of drug discovery
technologies – from gene identification through clinical development, and is focused on
the discovery of small molecule therapeutics. The company has research collaborations with
world class pharmaceutical companies, covering a broad range of therapeutic areas
including respiratory, cardiovascular, metabolic, and infectious disease, as well as
oncology and central nervous system disorders.
Inc. is a leading independent developer, manufacturer and marketer of high quality
off-patent pharmaceuticals. Founded in 1970, the company ranks among the top ten
independent companies in the approximately $7 billion U.S. generic pharmaceutical
business. With 1996 net sales of nearly $232 million, the company manufactures and
distributes a wide range of prescription drug products including antibiotics,
cardiovascular agents, and cancer treatments.
BASF Corporation is the third largest producer of chemicals and related
products in the United States, Canada and Mexico, with sales of $7.9 billion
in 2000. Based in Mount Olive, New Jersey, BASF Corporation is the North
American affiliate of BASF AG (Ludwigshafen, Germany), which is listed on the
New York Stock Exchange under the trading symbol "BF." "We don’t make a lot of
the products you buy. We make a lot of the products you buy better.®"
summarizes BASF’s diverse product mix including chemicals, polymers,
automotive and industrial coatings, colorants, nylon fibers and agricultural
products. BASF in North America employs more than 15,000 people at more than
is a health care company that develops, manufactures and markets clinical chemistry,
immunodiagnostics, diabetes, hematology and urinalysis systems for central laboratory,
point-of-care and self testing customer segments.
headquartered in Cambridge, MA, is a biopharmaceutical company principally engaged in
discovering and developing drugs for human healthcare through genetic engineering.
Biogen’s research and development activities are focused on novel products for
multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases and in
developmental biology and gene therapy.
BioSeekâs goal is to become the leading “Bionomics” company focused on the
generation and analysis of disease-relevant, biological activity information
that reduces the cost and improves the success of pharmaceutical drug
development. Recent genomics efforts and advances in combinatorial chemistry
have provided the pharmaceutical industry with enormous numbers of potential
new drug targets and new chemical entities. As a result, the bottleneck in the
creation of new drug products has moved from gene/target discovery to
selection, validation and development. BioSeek was formed in December 1999 by
a team of scientists from Stanford, the National Institutes of Health, and the
biotechnology industry to focus on the identification and development of
therapeutics in the post-genomics era.
BM-Science Brain & Mind Technologies Research Centre offers the knowledge,
the expertise and the methods of science through a wide range of services for
medical professionals, the related industries, and individuals.
The main areas of focus and expertise are:
Brain Research (focusing on EEG, MEG)
Systemic Psychophysiology / Neurological and Psychiatric Disorders
Twin and Multiples Psychobiology
Development and Testing of new scientific tools or instruments and
is one of the leading pharmaceutical companies in the world with more than 140
subsidiaries and over 22.000 employees, the Boehringer Ingelheim Corporation is
represented on every continent, the key areas include Europe, Japan and North America.
With a total sales turnover of more than 6 billion Deutsch Marks, Boehringer ranks
twentieth among the major pharmaceutical concerns worldwide.
Bristol-Myers Squibb is
a diversified worldwide health and personal care company whose principal businesses are
pharmaceuticals, consumer products, nutritionals and medical devices. It is a leading
maker of innovative therapies for cardiovascular, metabolic and infectious diseases,
central nervous system and dermatological disorders and cancer. The company is also a
leader in consumer medicines, orthopaedic devices, ostomy care, wound management,
nutritional supplements, infant formulas, and hair and skin care products.
is a global healthcare company headquartered in Emeryville, California, near San
Francisco. As one of the world’s largest biotechnology companies, Chiron employs more than
6,500 people in facilities on four continents. The company is uniquely positioned to
combine therapeutic, blood testing, vaccine and research strategies in many disease areas,
diseases and cancer.
The research strengths of Biomolecular Engineering are
the quality of our people and the range of their expertise. Our research skills in
molecular biology, cell biology and protein chemistry assist us in the search for new
pharmaceuticals, diagnostics and medical devices. The division is the lead member of the
Pharmaceutical and Human Health Sector. CSIRO
Biomolecular Engineering seeks collaborative arrangements with commercial and other
significant research and development groups. The scientific and commercial outcomes of our
research are carefully managed to maximise the benefits to our industry partners and to
protect the scientific knowledge for the benefit of Australia.
Pharmaceuticals, Inc. is focused on the discovery, development and commercialization
of novel antiinfectives to treat infections caused by drug resistant bacterial and fungal
pathogens. Daptomycin, the Company’s lead product, is a unique agent with potent
bactericidal activity that addresses the critical need for new antibiotics with potent
activity against resistant infections. The Company plans to begin Phase III clinical
trials of intravenous daptomycin in early 1999. Cubist is also applying its expertise in
microbiology, genomics and medicinal chemistry to identify other novel compounds with a
broad spectrum of activity against life-threatening infectious organisms such as
methicillin resistant Staphyloccocus aureus (MRSA) and vancomycin resistant
Cumbre Inc. is an exciting Dallas-based biopharmaceutical company that is
dedicated to meeting the challenge of infectious disease in the new
millennium. Cumbre plans to discover, develop and commercialize novel classes
of antimicrobial drugs for the treatment of bacterial and fungal infections.
Such infections represent a serious and growing medical problem in both
hospital and community settings. Worldwide annual sales of antibacterial and
antifungal agents amount to approximately $29 billion with projected sales of
over $44 billion by 2010. Cumbre combines a proprietary proteomics-based
drug discovery technology with target-directed screens and a lead compound
Devgen is a
functional genomics and drug discovery company located in Flanders (Belgium). Devgen will
enhance and accelerate the drug discovery process by using Caenorhabditis elegans –
the tiny worm that is well known in the academic world as a standard tool for the study of
animal developmental and cell biology.
The Dow Chemical Company
is the fifth largest chemical company in the world, with annual sales of more than $20
billion. The company provides chemicals, plastics, energy, agricultural products, consumer
goods and environmental services to consumers in virtually every country in the world.
Eli Lilly and Company
is a global research-based pharmaceutical corporation headquartered in Indianapolis,
Indiana, that is dedicated to creating and delivering pharmaceutical-based health care
solutions which enable people to live longer, healthier and more active lives.
EMC is classified as a
biotech company and focuses on the generation and biochemical investigation
of biologically and pharmacologically relevant organic compound collections.
Because of its basis in Combinatorial Chemistry EMC holds a leading position
in drug-discovery-technologies particularly in the areas of methods
development and high throughput synthesis of validated compounds.
Eurand is a
world leader in oral drug delivery. With manufacturing and research facilities in both the
United States and Europe, Eurand is ideally positioned to service the global
pharmaceutical market. Its technologies enable Eurand to provide extended release, delayed
release, targeted delivery, oral peptide delivery and taste-masked dosage forms, resulting
in optimization of drug absorption, reduction of side effects, improved palatability,
reduction in dosing frequency and improved patient compliance.
FMC Corporation is one
of the world’s leading producers of chemicals and machinery for industry, government and
agriculture. The company divides its businesses into four major segments: Performance
Chemicals, Industrial Chemicals, Machinery and Equipment, and Defense Systems.
Pharmaceuticals, Inc. develops and markets proprietary population
genomics and informatics technologies designed to improve the productivity
of the approximately $50 billion spent annually in drug discovery,
development and marketing. The Company’s technology has the potential to
become a major catalyst in validating drug targets, improving the success
rate of clinical trials and more profitably managing the life cycle of
approved drugs. It is estimated that these efficiencies could save up to
$200 million and two to three years in development time per drug.
global biopharmaceutical and diagnostics company, is focused on gene-regulating drug
discovery with an entirely new approach to medicine that could have profound potential in
the treatment of many serious diseases. The company also has a late-stage product in
clinical trials for systemic lupus erythematosus, an autoimmune disorder.
Genentech, Inc. is a
biotechnology company using human genetic information to develop, manufacture and market
pharmaceuticals that address significant unmet medical needs. Genentech commits itself to
high standards of integrity in contributing to the best interests of patients, the medical
profession, and its employees, and to seeking significant returns to its stockholders
based on the continued pursuit of excellent science.
Inc. (GI), Cambridge, Massachusetts, U.S.A., is a leading biopharmaceutical company
engaged in discovering, developing and commercializing therapeutic products to treat
serious medical conditions and to improve quality of life. Organized in December 1980, GI
currently focuses on compounds for the treatment of a wide range of diseases and
conditions, including anemia, hemophilia, cancer, bone damage, inflammatory conditions and
immune system disorders. Genetics Institute became a wholly owned subsidiary of American
Home Products Corporation in December 1996.
has the largest number of commercially used picking and gridding robots in the world.
Using our robotics and automation expertise, we tailor each project to your research needs
and provide fast, accurate results.
Corporation is a leading pharmacogenomics software company. The
company’s tools combine clinical, epidemiology, genetic, molecular biology,
and biochemistry applications into a single software environment that
enables scientists to accelerate genetic discoveries and pharmacogenomics.
Genomica’s software is used in the gene discovery process to develop custom
drug applications and accelerate time to market for new drugs. The software
supports a range of research activities and provides data that can be
accessed and used by pharmaceutical and biotechnology companies.
A highly diversified company, Genzyme uses a wide range of technologies to provide
human health care products and services. The company has extensive capabilities in sales
and marketing, manufacturing, research and development, and other disciplines necessary
for success in the health care market.
GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical
company with a powerful combination of skills and resources that provides a
platform for delivering strong growth in today’s rapidly changing healthcare
environment. GSK’s mission is to improve the quality of human life by enabling
people to do more, feel better and live longer. Headquartered in the UK and
with operations based in the US, the new company is one of the industry
leaders, with an estimated seven per cent of the world’s pharmaceutical
market. GSK also has leadership in four major therapeutic areas – anti-infectives,
central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In
addition, it is a leader in the important area of vaccines and has a growing
portfolio of oncology products. The company also has a Consumer Healthcare
portfolio comprising over-the-counter (OTC) medicines, oral care products and
nutritional healthcare drinks, all of which are among the market leaders.
Based on 2001 Annual Results, GSK had sales of £20.5 billion ($29.5 billion)
and profit before tax of £6.2 billion ($8.8 billion). Pharmaceutical sales
accounted for £17.2 billion ($24.8 billion) with new products representing 22%
of total pharmaceutical sales. GSK had four products with sales of over $1
billion and a total of 16 products with sales in excess of $500 million. GSK
has over 100,000 employees worldwide. Of these, over 40,000 are in sales and
marketing, the largest sales force in the industry. Over 40,000 employees work
at 107 manufacturing sites in 40 countries and over 16,000 are in R&D.
Milton S. Hershey believed in making the highest quality
product at an affordable price, ensuring consumers the best value for their money. This
philosophy continues to guide Hershey Chocolate North America, the largest division of Hershey Foods and its operating units.
GmbH – the high throughput experimentation company – is an independent,
privately-held high-science, high-technology company. The company was
launched specifically to develop, validate and apply high throughput methods
for the discovery and optimization of materials. hte GmbH focuses on
catalytic and separative processes. These processes are critical to the
global chemical industry, yet there are major unmet materials needs. hte
GmbH was founded in March 1999 and commenced operations in June 1999.
Through its novel research and development programs, ImClone is developing a pipeline for potential products
for cancer. Its innovative approaches have led to three distinct development programs:
cancer therapeutics, cancer vaccines and anti-angiogenesis agents. Each of these programs
has resulted in product candidates, some of which are advancing through clinical studies.
Based in Seattle, Washington, U.S.A., Immunex Corporation is a leading biopharmaceutical
company founded in 1981 that discovers, develops, manufactures and markets products to
treat cancer, autoimmune disorders and infectious diseases. American Home Products
Corporation holds a majority interest in Immunex.
Inc., founded in 1982, is a biopharmaceutical company focused on the development,
manufacture, and commercialization of diagnostic imaging and therapeutic products for the
detection and treatment of cancer and infectious diseases. Integral to these products are
highly specific monoclonal antibodies and fragments designed to deliver radioisotopes,
chemotherapeutic agents, or toxins to tumors and sites of infection.
Pharmaceuticals, we are combining our bioinformatics expertise with high-throughput
DNA sequencing to create information- based tools for drug discovery and development. Our
genomic databases, software, and biological reagents are rapidly becoming indispensable
research components for pharmaceutical and biotechnology companies because they provide
faster, easier, and more powerful ways for scientists to perform experiments, evaluate
data, and create drugs.
Johnson & Johnson,
with approximately 88,300 employees, is the world’s largest and most comprehensive
manufacturer of health care products serving the consumer, pharmaceutical, diagnostics and
professional markets. Johnson & Johnson has 164 operating companies in 50 countries
around the world, selling products in more than 175 countries.
is a drug discovery company focusing its research on the discovery and
pre-clinical phases of drug development. Research is conducted in the area
of nuclear receptors. Nuclear receptors are proteins in the cell nucleus and
act as receivers for a number of key hormones enabling the essential
regulation of organs in the body. Through the understanding of nuclear
receptors in drug design, new tissue selective drugs with fewer or no side
effects can be developed.
Lexicon Genetics is a drug
discovery company of the post-genome era, using gene knockout technology to
define the functions of genes for the discovery of pharmaceutical products. We
are expanding LexVision, our repository of new information on gene function,
to fuel our drug discovery programs in cancer, cardiovascular disease, immune
disorders, neurological disease, diabetes and obesity. To generate our
discoveries, we use our patented gene targeting and gene trapping technologies
to alter the DNA of specific genes in mouse embryonic stem (ES) cells. These
unique cells are cloned to create in vivo mammalian models of drug target
function enabling the discovery of pharmaceutically valuable proteins and drug
is a San Diego based biopharmaceutical company committed to the discovery, development,
marketing and distribution of novel, small molecule pharmaceutical products with novel
patterns of receptor-specific selectivity which provide better efficacy or side effect
profiles and more cost-effective alternatives to existing therapies.
Lilly is a leading innovation-driven pharmaceutical corporation. We are
developing a growing portfolio of best-in-class pharmaceutical products by
applying the latest research from our own worldwide laboratories and from
collaborations with eminent scientific organizations. We’re seeking answers for some of the world’s most urgent medical needs. As
our products save and improve lives, they also save overall health care costs:
they are often less expensive than other forms of health care, such as surgery
and hospitalization. We employ more than 35,000 people worldwide and market our medicines in 159
countries. Lilly has major research and development facilities in nine
countries and conducts clinical trials in more than 30 countries.
Welcome to the T.J.
Lipton Home Page, brought to you by the Lipton Internet team! Our mission is to
provide net-surfers a place to explore information about Lipton, and to participate as a
committed member of the Internet community.
Inc. is a global contract research and development company assisting customers in
accelerating the drug discovery process through innovation and technology in organic
synthesis. MediChem is dedicated to becoming a valued collaborative partner in chemistry
research through excellent scientific expertise, communication, and an outstanding track
record since 1987.
Merck & Co., Inc.
is a leading research-driven pharmaceutical products and services company. Merck
discovers, develops, manufactures and markets a broad range of innovative products to
improve human and animal health. The Merck-Medco Managed Care Division manages pharmacy
benefits for more than 40 million Americans, encouraging the appropriate use of medicines
and providing disease management programs.
The prevention and treatment of disease… That is the
mission, the heritage and the business of Merck Frosst Canada. Since the
day Charles E. Frosst founded the Company in Montréal at the turn-of-the-century, Merck
Frosst has been a leader in pharmaceutical research — developing and producing medicines
that respond to the health care needs of Canadians and people around the world.
is the world’s leading animal healthcare company dedicated to the research,
development, manufacture and delivery of innovative pharmaceuticals and
vaccines for use by veterinarians, farmers and pet owners to improve the
health, well-being and performance of all animal species. The company is
also market leader in the development and production of poultry breeding
Founded in early 1993, Millennium
Pharmaceuticals‘ principal objectives are to accelerate the discovery of
disease-related genes and to produce validated targets and drug leads to enable the
development of new, proprietary therapeutic and predictive medicine applications. The
Company’s research programs are focused on major common diseases which are under-served by
current therapeutic alternatives, including obesity, type II diabetes, cardiovascular
diseases, oncology, central nervous system disorders, respiratory disease, bacterial
disease and fungal disease. Millennium has entered into significant, multi-year research
and development partnerships with five major pharmaceutical partners. These alliances
cover seven disease areas and provide over $300 million in committed funding. Located in
Cambridge, Massachusetts, Millennium currently employs over 400 people.
is made up of business sectors. Three of the sectors – Agricultural, Nutrition &
Consumer Products and Pharmaceutical – are built around currently strong ongoing
operations. Two others – Health & Wellness and Sustainable Development –
pursue emerging opportunities.
Nabisco is a $7.7
billion multinational food business, manufacturing more than 200 brands and 8,000 products
in 85 countries.
Nanosyn, Home of
Nanoscale Combinatorial Synthesis Inc. We produce organic combinatorial libraries with
unique design features as well as provide access to an existing compound collection
approaching 100,000 individually purified and analytically characterized small molecules.
All libraries are provided in 96 and 384 well plates, ready for redistribution or
assembled a chemical library of diverse, low molecular weight organic molecules for lead
compound identification. The Company has implemented robotic screening capabilities linked
to its library of compounds that facilitate the rapid identification of new drug
candidates for multiple drug targets. The Company believes that the utilization of
high-throughput screening and medicinal and peptide chemistry will enable the rapid
identification and optimization of lead molecules.
Neurogen is an
emerging pharmaceutical company leading the design and development of a new generation of
small molecule neuropharmaceuticals. Neurogen develops drugs to treat large markets with
currently unmet needs through designing drug candidates (pills) with improved efficacy and
fewer side effects than current therapies. Neurogen’s ten drug development programs
include drugs to treat anxiety, obesity, schizophrenia, sleep disorders, dementia,
depression, stress-related disorders and epilepsy.
As a leading force in healthcare for over a century, Novartis is committed to improving the global quality
of life through our broad portfolio of products and services in pharmaceuticals, generics,
consumer health, and eye care and opthalmics. Novartis was formed by the merger of Ciba
Inc. is a biopharmaceutical company involved in the discovery and development of novel
drugs to treat or cure major human diseases. Independently, and in collaboration with four
pharmaceutical partners, including Pfizer, Ciba-Geigy, Hoechst Marion Roussel, and the
Wyeth-Ayerst Research division of American Home Products, Oncogene Science is currently
pursuing 30 disease targets in areas such as cancer, cardiovascular disease, infectious
diseases, and other diseases involving gene regulation. The Company is also developing
cancer diagnostic products.
founded in August 1994, is a privately-held biotechnology company whose mission is to be
the pre-eminent biopharmaceutical company utilizing developmental biology to create
therapeutics that will significantly improve the quality of life by activating the body’s
ability to repair and regenerate. Developmental biology is the study of how cells, tissues
and organs change as they interact during development. Ontogeny’s research is based on the
process whereby an organism changes its size, shape and organization from a fertilized egg
to a mature individual. The same processes and molecules that are active during
development are reactivated in adult regenerative processes. Ontogeny is identifying ways
to rejuvenate damaged systems by looking at the signaling processes of cells during
development and restoring them in adults to trigger repair and regeneration.
BioSciences, Inc. is a leading provider of products, services and
technologies for SNP scoring and genetic diversity analyses. Orchid has
developed SNP-IT, its proprietary SNP analysis technology, and markets
SNPstreamTM instruments and SNPwareTM consumables that rapidly generate highly
accurate, cost effective SNP information. SNP-IT is usable in environments
ranging from small-scale laboratories to large commercial facilities. Its
versatility also has enabled Orchid to partner with industry leaders to make
SNP-IT-enabled products available on a wide variety of instrument platforms.
Orchid also provides high throughput SNP scoring services to pharmaceutical,
biotechnology and academic customers through its MegaSNPatron facility, and
DNA testing through its GeneScreen facilities that conduct paternity,
forensics and transplantation testing. Through its Pharmaceutical Value
Creation business, Orchid also seeks to identify proprietary medical
applications of SNPs. More information on Orchid can be found at its web site
Organon is a
pharmaceutical business unit of Akzo Nobel. It is registered in Oss, the Netherlands. The
company has developed and manufactured ‘prescription-only’ drugs, principally
hormone preparations, since 1923. The company’s most successful products are oral
contraceptives (Marvelon and Mercilon), fertility hormones (Puregon and Pregnyl) and
hormone replacement products for menopausal and post-menopausal women (Livial). But it has
other important products which are used in psychiatry (Remeron, Risperdal and Tolvon) and
in the prevention of thrombosis (Orgaran).
MDS Panlabs, Inc.
is a contract research organization providing scientific research services supporting drug
discovery, development, and process improvement to the pharmaceutical industry. Specific
services include: natural products and new drug discovery; strain and yield improvement
using molecular or classical approaches; and compound profiling, synthesis, isolation, and
Inc. is a development stage biopharmaceutical company that is developing and testing
products for diagnostic imaging, and peptide-based analogues that may have a wide range of
pharmaceutical applications. PLTN’s first two products are LeuTech(tm), a radiolabeled
monoclonal antibody for infection imaging that has completed a company-sponsored Phase I
trial, with the Company-sponsored Phase II trial for the diagnosis of equivocal
appendicitis currently underway; PT-11, a peptide based infection imaging agent designed
to address the Japanese diagnostic imaging market with development support from license
and milestone payments from Nihon Medi-Physics of Japan; PT-14, a peptide-based sexual
dysfunction therapeutic; and PT-5, a radiolabeled peptide-based cancer therapeutic that is
in early stage development.
Inc. is a privately held start-up biotechnology company founded in 1996
with research and development facilities located in Monmouth Junction, NJ,
near Princeton. The company has six patents from the U.S. Patent and
Trademark Office covering microtransponder-based assays. PharmaSeq’s
strategy is to apply microtransponder technology initially to DNA diagnostic
assays, a U.S. market estimated to reach over $1 billion by the year 2002
and then move forward in genomics, forensics, communications, pharmaceutical
drug discovery, RFID and other areas.
PHASE-1 is a
molecular and high throughput toxicology contract laboratory. We specialize in development
and application of advanced assays for prioritization of lead compounds and understanding
mechanisms of toxicity. For example, PHASE-1 is the only contract testing organization
that can synthesize and analyze its own high density gene arrays in-house. Our arrays are
designed specifically for toxicology. In addition, PHASE-1 is a pioneer in the field of
bioinformatics applied to molecular toxicology. The primary goal of the scientists at
PHASE-1 is to advance the field of molecular toxicology and to share these advances with
the drug discovery and toxicology communities.
The ultimate objective of Pharmacia & Upjohn‘s research is to
develop new, innovative medicines that can help people around the world live longer and
Located in Princeton, New Jersey, Pharmacopeia is a leader in drug discovery combining small
chemistry, high-throughput screening, and informatics. Through its wholly-owned
subsidiary, Molecular Simulations Inc., Pharmacopeia
provides software sales and services to the life and materials science industries.
Two of the leading global contract research
organizations have joined forces to become the third largest CRO in the world. With this
merger, PPD Pharmaco has created the
standard-setting partner for clinical development. On the one hand, we bring you
far-reaching experience and therapeutic expertise. On the other, innovative technology and
project management systems. The result is an unmatched resource for speeding
pharmaceuticals, medical devices and biotechnology products to market.
PTC Therapeutics, Inc. has developed several novel, proprietary,
and complementary platform technologies that rapidly identify small
molecules affecting the availability, or utilization, of specific RNAs. The
technologies are applicable to a diverse set of targets. These platforms
identify lead compounds that alter the post-transcriptional control of the
expression of specific genes and/or RNA function. In addition to their broad
applicability to diverse therapeutic targets, these technologies are fast,
cost-efficient, and performed under physiological conditions thereby
enabling parallel screens to be undertaken simultaneously for a large number
of drug discovery programs. PTC’s platform technologies include:
(Targeted Ribonucleic Acid Chemistry) – for the rapid screening and
identification of small molecules that bind directly to RNA with high
specificity and modulate RNA utilization. TRAC is performed under
physiological conditions that allow targeted RNAs to retain their native
Translation – for the screening and identification of small
molecules that modulate different aspects of translation initiation,
elongation and termination events in order to regulate the expression of
genes relevant to both genetic and infectious diseases.
Turnover – for the screening and identification of small molecules
that affect specific steps in cellular mRNA turnover and processing
pathways. Molecules identified by this procedure can promote either
substantial increases or decreases in mRNA levels.
Rib-X Pharmaceuticals, Inc. is a New
Haven, CT-based small molecule drug discovery company focused on the
structure-based design of classes of anti-infective agents. Our technology
platform is based on the high resolution crystal structure of the 50S subunit
of the ribosome obtained by Thomas Steitz, Peter Moore and their co-workers.
Since the publication of their work (Science 289:905-929), their
crystallography studies have advanced to include analysis of the structure of
known antibiotics bound to the ribosome. The structural data from the
antibiotic binding studies will be used at Rib-X to prime parallel lead
optimization programs focused on evaluating new chemistry ideas about
antibiotic interactions with the multiple binding domains or drug targets
within the 50S subunit. Using proprietary computational chemistry tools
provided by another scientific founder, Yale Professor William Jorgensen,
coupled with chemical synthesis, biochemistry and crystallographic analysis,
we aim to discover new compounds useful as anti-infective agents.
The Roche Group is
one of the world’s leading research-based healthcare groups active in the discovery,
development, manufacture and marketing of pharmaceuticals and diagnostic systems. The
Group is also one of the world’s largest producers of vitamins and carotenoids and of
fragrances and flavors.
Rohm and Haas is a
manufacturer of specialty chemicals and plastics. Its products are those
"invisible" ingredients that make things work better and last longer. The
company’s expertise in polymer design and small-molecule chemistry, along with a tradition
of dynamic customer service, have made it one of the world’s premier suppliers of
is a research-based company engaged in the discovery, development, manufacturing and
marketing of pharmaceutical and health care products worldwide. The Company’s central
strategic objective is the discovery and development of novel therapeutics that can
improve people’s health and extend lives.
Molecule Therapeutics, Inc. (SMT) is a privately held drug discovery
company. SMT uses proprietary whole-cell high throughput screening systems
to discover novel compounds of therapeutic value for a broad range of
disorders including cancer and immunological, infectious and metabolic
diseases and for applications in agriculture.
In 1861, Ernest Solvay, a man with a passionate interest
in science, research and innovation, developed a revolutionary ammonia-soda process for
producing sodium carbonate. The Solvay Group was
founded in 1863 to exploit this process, and has grown to become a global group of
chemical and pharmaceutical companies specializing in four sectors: Chemicals, Plastics,
Processing and Pharmaceuticals.
SOUTHERN RESEARCH INSTITUTE (SRI) is an independent, 501-(c)-3,
not-for-profit center for scientific research with a staff of nearly 600,
including scientists, technical, and staff support personnel. In late 1999 the
Institute affiliated with the University of Alabama at Birmingham. Both
institutions are recognized leaders in many fields of scientific inquiry and
have collaborated successfully in the past and this new relationship will
foster even greater, more fruitful cooperation in the future. The Institute
works under contract for both public and private sector clients. SRIâs High
Throughput Screening (HTS) program is a division of the Cancer Therapeutics
and Immunology Department. The HTS program has integrated a large number of
biochemical and cell-based screening assays from all Drug Discovery and
Development Divisions within SRI, including cancer therapeutics, immunology,
toxicology, and infectious disease. We specialize in determining the most
cost-effective method for evaluating compound libraries without compromising
assay sensitivity. Additionally, we welcome collaborations with companies in
possession of compound libraries that have an interest in evaluating potential
antiviral, anti-microbial or anti-cancer activity in addition to toxicological
profiles of their compounds on a fee for service or compound licensing basis.
is pioneering the emerging field of combinatorial
materials science by applying proprietary combinatorial methodologies to discover
and develop new materials for the electronics and chemical industries. Through its
technologies, the company is able to synthesize and screen materials, formulations, and
microdevices up to 100,000 times faster than conventional "small batch"
procedures. Symyx expects its ability to evaluate millions of inorganic, organic and
organometallic compounds will lead to the rapid, cost effective discovery of materials for
high-value products and applications.
SCYNEXIS™ provides a full range of synthesis chemistry services to the
life sciences industry, From Concept To Clinic™. We offer novel hit generation
compounds, hit explosion, lead optimization and radiochemistry services as
well as the production of clinical samples in our GMP facility. Every day,
SCYNEXIS is demonstrating that our people and technology meet the challenges –
and even reshape – todayâs pharmaceutical discovery process. The result: our
customers are receiving unparalleled speed and efficiency that revolutionize
the limits imposed on todayâs discovery chemistry lab. SCYNEXIS is increasing
the productivity and speed of the pharmaceutical discovery process by removing
the boundaries of the chemistry lab. By utilizing our patented MEDCHEM-FACTORY™
process and other proprietary technology platforms, SCYNEXIS is quickly
emerging as a company with special expertise in the areas of hit explosion and
lead optimization. Harnessing technology in ways never seen before in
discovery labs, we are uniquely positioned to meet the specific needs of our
customers by providing targeted, and timely, expertise that is tailored to
individual projects. Our process chemistry team is meeting the most demanding
challenges in custom synthesis, chemical process development and GMP
production. Our experienced staff is housed in world-class facilities
including a newly constructed GMP manufacturing suite designed for
versatility. With the finest processing and purification equipment, our staff
can deliver complex molecules from gram to kilogram scale. In addition,
SCYNEXIS designs routes to and produces radio-chemicals for every stage of the
drug discovery process in our new, specially designed Radiochemistry facility.
Staff with many years of Radiochemistry experience are able to develop highly
efficient routes to the desired radio-labeled compounds, to the quality and
deadline customers expect. From Concept To Clinic, Weâre Working On Tomorrowâs
Chemistry Solutions Today.
is a major French research-based pharmaceutical firm. Its Research Division, with a
staff of 1350 specialised researchers, develops highly innovative drugs, mainly in the
areas of central nervous system, cardiovascular and internal medicine.
The newest name in human cell
transformation has a long and respected history. Since 1986 you’ve relied
upon the International Institute for the Advancement of Medicine (IIAM) for
your research needs. Now, in order to extend and enhance service to you,
IIAM has formed Tissue Transformation
Technologies (T-Cubed) to advance the processing technologies of the
perfused organ program. T-Cubed is the solution for human tissue and organs
that have been otherwise rendered unsuitable for transplantation. T-Cubed’s
advancing technology and growing expertise converts human organs and tissues
into optimum in vitro models for research, drug metabolism / toxicity
studies and compound screening (HTS).
Tripos, Inc. is a
leading discovery research organization providing discovery informatics software, systems
integration, chemical libraries and services for new compound research in life science
is a drug discovery and development company that has pioneered the application of
structure-based drug design, a powerful drug discovery strategy to design orally
deliverable, small molecule drugs. The Company is using this technology to design novel
therapeutics for the treatment of HIV infection and AIDS, multidrug resistance in cancer,
hemoglobin disorders, autoimmune disease, inflammation and hepatitis C.
is a premiere global marketer of vital prescription drugs and renowned consumer products
that enrich the personal health and enjoyment of people around the world.
Healthcare is a leader in the research and development, manufacturing and marketing of
a broad range of consumer health care products. With 1996 U.S. sales of $1.4 billion,
Whitehall-Robins is one of the largest over-the-counter (OTC) health care companies in the
United States. Headquartered in Madison, New Jersey, U.S.A., it employs 1,700 people in
the United States. Of the thousands of products in the U.S. non-prescription market today,
three of the five top sellers are Whitehall-Robins products: Advil®, Robitussin® and
Centrum®. Three recently introduced Whitehall-Robins OTC products include Orudis® KT, an
adult analgesic, launched in November 1995; Axid® AR, an acid reducer, launched in July
1996; and Children’s Advil®, a pediatric analgesic, launched in September 1996.
This is a World-Wide Web server run by the Center for Genome Research at the Whitehead Institute
for Biomedical Research in Cambridge, Massachusetts, USA. It contains information on
map and sequence releases, software and people at the Genome Center.
is a major research-oriented enterprise serving the health needs of people in 145
countries. Wyeth-Ayerst has a long history of pioneering developments in pharmaceuticals
and is a leader in the areas of women’s health care, cardiovascular and metabolic disease
therapies, anti-inflammatory agents, central nervous system drugs, oncology/immunology,
infectious diseases, anti-infectives, vaccines and generic pharmaceuticals. Wyeth-Ayerst’s
principal products include Premarin® (conjugated estrogens tablets, USP), Prempro™
and Premphase® (conjugated estrogens/medroxyprogesterone acetate tablets), Effexor®
(venlafaxine hydrochloride tablets), Lodine® (etodolac capsules and tablets), Naprelan®
(naproxen sodium controlled-release tablets), Ziac® (bisoprolol
fumarate/hydrochlorothiazide tablets), Verelan® (verapamil HCl pellet-filled capsules)
and Zosyn® (sterile piperacillin sodium/tazobactam sodium). The organization includes
Wyeth-Ayerst Laboratories, Wyeth-Ayerst International, Inc. and Wyeth-Ayerst Research.
X-Ceptor Therapeutics is a privately held biopharmaceutical company
focusing on research in the rapidly developing field of orphan nuclear
receptors that serve as the molecular targets for the discovery of novel small
molecule pharmaceutical products for the treatment of human diseases. X-Ceptor
has developed an integrated approach to drug discovery drawing from our
in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor’s
advantage lies in its understanding of orphan nuclear receptors and their
signaling pathways, as well as its proprietary ability to employ these orphan
nuclear receptors in transcriptional and biochemical based assays to discover
novel therapeutic agents. X-Ceptor is developing a powerful technology
platform that includes our in-house, state-of-the-art screening, combinatorial
chemistry and molecular disease association using functional genomics. The
development of these technologies offers the ability to streamline the
discovery of new therapeutics and provides an untapped opportunity to expand
drug discovery on these biologically and therapeutically important molecular
XENOTECH offers one of the most extensive selections of products for drug
metabolism-related research, including liver and pulmonary microsomes and S9,
cryopreserved hepatocytes from human and six other toxicologically relevant
species, antibodies directed against CYP enzymes, recombinant CYP’s, and bDNA
Zeneca is a leading
international bioscience group active in three main areas of business – Pharmaceuticals,
Agrochemicals and Specialties – which provide products and services to improve human
health, nutrition and quality of life around the world.
is a targeted bioinformatics-driven company dedicated to the discovery and
development of novel therapeutic agents used in the treatment and prevention
of human illness.
These web sites are
full of links to many pharmaceutical and biotechnology companies worldwide.
Limited intends to establish an interactive, one-stop location on global biotechnology
activities. To date we have identified over 300 companies starting with "A" to
"E", of which 170 are linked to their respective web site and 110 to NASDAQ.
Over the next three months we anticipate that over 2500 companies will be listed on
Bio-Corporate and that several companies and organisations will be actively participating
in our BioLogo scheme, Bio-Wire, Bio-Vacancy and Bio-Mart services.
RUU Pharmaceutical Companies Links,
represents approximately 100 U.S. companies that have a primary commitment to
pharmaceutical research. These companies are discovering, developing and bringing to
market medicines that improve our health and quality of life–as well as reduce the
overall cost of healthcare.
If you know your
company’s web site URL and would like us to list it, send a message to firstname.lastname@example.org. The
Laboratory Robotics Interest Group links to many other organizations in our web
site. See how to return the favor on our Link-To-Us page.